Stifel analyst Derek Archila reiterated a Buy rating and $8.00 price target on PhaseBio Pharmaceuticals Inc. (NASDAQ: PHAS) after hosting ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE